Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Gain (Loss), Foreign Currency Transaction, before Tax

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is NewAmsterdam Pharma Company's gain (loss), foreign currency transaction, before tax?
NewAmsterdam Pharma Company (NAMS) reported gain (loss), foreign currency transaction, before tax of -$1.61M in Q1 2026.
How has NewAmsterdam Pharma Company's gain (loss), foreign currency transaction, before tax changed year-over-year?
NewAmsterdam Pharma Company's gain (loss), foreign currency transaction, before tax decreased by 137.6% year-over-year, from $4.29M to -$1.61M.
What is the long-term trend for NewAmsterdam Pharma Company's gain (loss), foreign currency transaction, before tax?
Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's gain (loss), foreign currency transaction, before tax has grown at a 66.6% compound annual growth rate (CAGR), from $1.71M to $13.14M.